PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 2118188

Selecting drug combinations based on total equivalent dose (dose intensity)

R Simon·E L Korn
View original source ↗Export metadata ↓

Abstract

We describe a mathematical model for selecting cytotoxic drugs and dosages for a combination regimen based on the antitumor activities of the drugs given as single agents and their organ-specific maximum tolerated doses. The regimen defined maximizes an approximate measure of antitumor effect subject to constraints on combined toxicity. This approach does not assume that the underlying dose-response curve is steep; nor does it assume that maximally dose-intense regimens are clinically appropriate in all situations. Whether the identified regimen is superior to standard treatments should be determined by prospective, randomized clinical trials. Determining which drugs to combine and in what proportions to combine them offers combinatorially huge numbers of possibilities. The method described here offers one approach to identifying combinations worthy of evaluation in prospective trials.

Explore related subjects

AltretamineAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCisplatinCyclophosphamideDose-Response Relationship, DrugDoxorubicinDrug Screening Assays, AntitumorDrug SynergismFemaleHumansModels, TheoreticalOrganoplatinum CompoundsOvarian NeoplasmsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Simon, E L Korn. 1990-09-19. Selecting drug combinations based on total equivalent dose (dose intensity). https://doi.org/10.1093/jnci%2F82.18.1469

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2004

Recurrent ovarian cancer: how important is it to treat to disease progression?

Ovarian cancer is increasingly recognized as a chronic disease whose treatment is often characterized by administration of multiple, sequential active agents, each of which may or may not be accompanied by a tumor response. Despite the large proportion of patients who relapse and undergo longer-term treatment, the question of optimal treatment duration has not been fully addressed to date. For patients who progress on therapy, the answer is straightforward: they are switched to another active agent, presumably having a different mechanism of action from previous therapies with, ideally, limited overlapping toxicities. However, for patients who remain in partial response or who have stable disease, the answer is less apparent and less clear. The majority of oncologists believe that treatment beyond 6 cycles of a given therapy does not provide any additional benefit to patients. There are some data to support that treatment strategy. However, with the advent of new, less toxic agents, treatment to progression should be further explored. Agents that are potentially well suited for extended treatment intervals may include such properties as absence of cumulative toxicity, non-cross-resistance, positive benefit on quality of life, and convenient schedule. A number of active agents in ovarian cancer (platinum, paclitaxel, topotecan, liposomal doxorubicin, docetaxel, gemcitabine, and etoposide) will be reviewed in the context of what is known about cumulative toxicity, potential adverse effects on patients' quality of life, and evidence addressing the potential benefits of longer-term treatment.

Altretamine↗